Results from the COAPT study continue to roll in, and it was all positive news for the MitraClip team at the TCT conference in San Francisco this month.

Frequent and persistent hot flashes during menopause can majorly raise women’s risk of clinical CVD events in the following 20 years, researchers reported at the 30th Annual Meeting of the North American Menopause Society.

Medtronic announced Sept. 27 that it had received FDA approval to launch an early feasibility study for its Intrepid TMVR system using a minimally invasive transfemoral access approach.

Tests commissioned by NBC News have revealed that vitamin E—the suspected culprit behind some 800-plus reported cases of vaping-related lung illness—is present in many THC cartridges sold on the black market, alongside other toxicities like pesticides and myclobutanil.

A shortened, three-month course of dual antiplatelet therapy might be a safer bet than 12-month treatment for patients at a high risk of bleeding after PCI and implantation of a drug-eluting stent.

French company Robocath announced Sept. 24 it had successfully completed its first two in-human coronary angioplasties performed with assistance from its R-One robotic platform.

Five-year results of the ABSORB III trial suggest that, while target lesion failure and scaffold thrombosis have remained apparent in patients implanted with bioresorbable vascular scaffolds, the poor outcomes associated with BVS seemed to subside after three years, when the stents had completely dissolved.

Twenty-six percent of heart attack survivors are confused about the role aspirin plays in secondary MI prevention, according to a recent survey from Bayer—a phenomenon that can be attributed in large part to an onslaught of conflicting headlines in the news this summer.